# Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/brivanib-versus-sorafenib-as-first-line-therapy-in-patients-with-unresectable/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Philip J. Johnson,Shukui Qin,Joong‐Won Park,Ronnie T.P. Poon,Jean‐Luc Raoul,Philip A. Philip,Chih‐Hung Hsu,Tsung‐Hui Hu,Jeong Heo,Jianming Xu,Ligong Lu,Yee Chao,Éveline Boucher,Kwang‐Hyub Han,Seung Woon Paik,Jorge Alberto Robles-Aviña,Masatoshi Kudo,Lünan Yan,Abhasnee Sobhonslidsuk,Д. В. Комов,Thomas Decaens,Won Young Tak,Long‐Bin Jeng,David Liu,Rana Ezzeddine,Ian Walters,Ann‐Lii Cheng |
| Citations | 778 |
| DOI | 10.1200/jco.2012.48.4410 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2012.48.4410?role=tab |
| OpenAlex ID | https://openalex.org/W2046000826 |
| PMID | 23980084 |
| Type | article |
| Year | 2013 |

## Paper authors

- [Ligong Lu](https://scholariq.org/researchers/ligong-lu/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Paper topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Fibroblast Growth Factor Research](https://scholariq.org/topics/fibroblast-growth-factor-research/)
- [Liver physiology and pathology](https://scholariq.org/topics/liver-physiology-and-pathology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.